You're talking about opportunity cost, I don't know enough to speak to that, but that there is something else just as good or better doesn't make it any lesser.

You're talking about opportunity cost, I don't know enough to speak to that, but that there is something else just as good or better doesn't make it any lesser. At this point, the author of this article is more expert than I'll ever be, I'd assume that he has reasons to consider mRNA a low hanging fruit compared to existing tech like protein-subunit or adenovirus for infectious diseases. And against DNA-based, well mRNA has beat it to the punch in being used at scale in humans, so that's possibly one advantage.